Literature DB >> 30712893

Baricitinib for systemic lupus erythematosus - Authors' reply.

Daniel J Wallace1, Richard A Furie2, Yoshiya Tanaka3, Stephanie de Bono4, Robert W Hoffman4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30712893     DOI： 10.1016/S0140-6736(18)32749-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).

Authors:  H Babaoglu; J Li; D Goldman; L S Magder; M Petri
Journal:  Lupus       Date:  2019-11-06       Impact factor: 2.911

2.  Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial.

Authors:  M Waibel; H E Thomas; J M Wentworth; J J Couper; R J MacIsaac; F J Cameron; M So; B Krishnamurthy; M C Doyle; T W Kay
Journal:  Trials       Date:  2022-05-23       Impact factor: 2.728
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.